Xenon plunges 24% on trial pause; Netflix downgraded by Wells Fargo

Price ActionAnalystEarnings
โดย Investing.com·US·Read original
Summary · why it matters

Xenon Pharmaceuticals plunged 24% in premarket trading after submitting a New Drug Application to the U.S. Food and Drug Administration for azetukalner as a treatment for focal seizures in epilepsy while voluntarily pausing new patient enrollment in ongoing Phase 3 trials for major depressive disorder and bipolar depression. Netflix slipped 2.1% after Wells Fargo downgraded the streaming giant to Underweight from Equal Weight and cut its price target to $57 from $80, citing weakening engagement trends. Array Technologies fell 3.1% to $4.11 after UBS downgraded the solar tracking company to Neutral from Buy and cut its price target to $5 from $10, pointing to a shift from payment-in-kind to cash payments on preferred dividend obligations that UBS estimates will total roughly $162 million in cumulative cash payments through 2030. Steel Dynamics dropped 3.4% after guiding third-quarter 2026 earnings to $5.34 to $5.38 per diluted share, below the analyst consensus of $5.60. Frontline fell 6% as the tanker company went ex-dividend for a combined payout of $3.41 per share, made up of a regular second-quarter dividend of $2.61 and a special dividend of $0.80 funded by the sale of two very large crude carriers.

Impact on stocks 6

Energy Transition & Power Demand▼ · 1 stocks
Array Technologies Inc
ARRY
▼ NegativeCapitalrelevance

UBS downgraded Array Technologies to Neutral and cut its price target to $5 from $10 on preferred dividend cash-payment concerns.

Communication Services▼ · 1 stocks
Netflix Inc
NFLX
▼ NegativeCapitalrelevance

Wells Fargo downgraded Netflix to Underweight and cut its price target to $57 from $80, citing weakening engagement trends.

Critical Materials & Supply Chain▼ · 1 stocks
Steel Dynamics Inc
STLD
▼ NegativeCapitalrelevance

Steel Dynamics guided Q3 2026 earnings to $5.34-$5.38 per share, below the $5.60 analyst consensus.

Biotech & Genomic Medicine▼ · 1 stocks
Xenon Pharmaceuticals Inc
XENE
▼ NegativeRegulationrelevance

Xenon voluntarily paused new patient enrollment in ongoing Phase 3 trials for major depressive disorder and bipolar depression while submitting its azetukalner NDA to the FDA.

Consumer Discretionary▲ · 1 stocks
Energy▲ · 1 stocks
© 2026 MarketDXNews